A recent study conducted by researchers at Brown University strengthens the emerging link between the shingles vaccine and a lower risk of dementia in older adults. The research, published in The Annals of Internal Medicine, examined electronic health records and Medicare claims for 509,926 U.S. adults aged 66 and older who were admitted to skilled‑nursing facilities.
Key Findings
Participants who received at least one dose of the recombinant shingles vaccine, marketed as Shingrix, showed a 24% relative reduction in dementia diagnoses over a four‑year follow‑up period compared with those who never received the shot. The investigators emphasized that the results demonstrate an association, not a proven cause‑and‑effect relationship.
Expert Commentary
Dr. Ajeet Sodhi, a clinical neurologist and neuro‑interventionalist based in Orlando, Florida, called the finding “remarkable” and noted that it aligns with several prior studies suggesting similar benefits. “This is maybe the third or fourth study, and they all came to the same conclusion,” Sodhi said. He added that the vaccine’s role in preventing shingles‑related complications may be a key factor.
Possible Explanations
Researchers propose several mechanisms for the observed association. By preventing shingles, the vaccine may reduce the incidence of post‑herpetic neuralgia and other nerve‑damage complications that could contribute to cognitive decline. Additionally, the varicella‑zoster virus has been linked to vascular events such as stroke, which are known risk factors for vascular dementia.
Broader Health Benefits
Recent medical literature also points to cardiovascular advantages from the shingles vaccine. A study released the same week reported a clinically significant reduction in both heart attacks and strokes among vaccine recipients. While these findings are encouraging, Dr. Sodhi cautioned that the vaccine is not currently classified as a direct treatment for cognitive impairment.
Vaccination Recommendations
The Centers for Disease Control and Prevention (CDC) recommends two doses of Shingrix for adults 50 and older, as well as for adults 19 and older who are immunocompromised. The vaccine is FDA‑approved to prevent shingles and its complications, not to prevent or treat dementia.
Funding and Disclosure
The study received funding from GSK, the manufacturer of Shingrix. The authors stated that the company had no role in the study’s design, data analysis, or manuscript preparation.
What Seniors and Families Should Do
For older adults concerned about memory loss or with a family history of dementia, experts advise early medical evaluation. “The sooner you seek evaluation, the better it is for the treatment,” Dr. Sodhi said. Early detection remains the most effective strategy for managing cognitive decline.
Conclusion
While the Shingrix vaccine’s primary purpose remains the prevention of shingles and its painful complications, emerging evidence suggests it may also play a role in reducing dementia risk and improving cardiovascular health. Seniors are encouraged to discuss vaccination options with their healthcare providers as part of a comprehensive approach to healthy aging.
Original reporting: Fox News (HLL/CB) — read the source article.
